Isavuconazole (BAL4815; trade name Cresemba) is a triazole antifungal drug. Its prodrug, isavuconazonium sulfate (BAL8557), was granted approval by the U.S. Food and Drug Administration (FDA) on March 6, 2015. Isavuconazole has been approved for treatment of invasive aspergillosis and invasive mucormycosis in adults ages 18 years and older. Both infections are caused by mold and fungi common to the environment, and occur in individuals who are immunosuppressed or have other complicating conditions, such as diabetes or lung disease.
Khunt, Rupesh Chhaganbhai; Rafeeq, Mohammad; Merwade, Arvind Yekanathsa; Deo, Keshav. A process for the preparation of isavuconazonium sulfate. WO 2016016766. (Assignee Wockhardt Limited, India)
Zhou, Caie; Huang, Song; Dong, Qiang; Liang, Zhengquan. Preparation of isavuconazonium sulfate. CN 106883226. (Assignee Chengdu Lvlin Technology Co., Ltd., Peop. Rep. China)
Zhou, Waihai; Yin, Qiming; Gong, Renwei; Han, Dong; Wu, Chuan; Zhou, Huaxin; Ni, Haihua; Hao, Xiubin. Method for preparing isavuconazonium sulfate by oxidation-reduction reaction. CN 106916152. (Assignee Yangtze River Pharmaceutical Group Co., Ltd., Peop. Rep. China)
